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Background: Ferritin is known to be associated with insulin resistance (IR) and oxidative stress; however, recent studies 
have shown that there is an association between ferritin and anti-oxidative status. To date, the biphasic response of 
ferritin to oxidative stress has not been fully evaluated. Thus, we investigated the association between ferritin and IR and 
anti-oxidative status in obese and non-obese women.
Methods: We evaluated the homeostasis model assessment of insulin resistance (HOMA-IR) and total anti-oxidant status 
(TAS) in a total of 111 healthy women between the ages of 32 and 68 years.
Results: In all of the study subjects, ferritin levels were positively correlated with age (r = 0.38, P < 0.001), body mass index 
(r = 0.24, P = 0.01), TAS (r = 0.38, P < 0.001) and HOMA-IR (r = 0.20, P = 0.04). In the subgroup analysis, ferritin levels were 
correlated with age (r = 0.39, P < 0.001) and TAS (r = 0.43, P < 0.001) in the non-obese group and with insulin (r = 0.50, P = 
0.02) and HOMA-IR (r = 0.52, P = 0.01) levels in the obese group. On stepwise multiple linear regression analysis, ferritin 
was found to be independently associated with TAS (B = 177.16, P < 0.0001) in the non-obese group and independently 
associated with HOMA-IR (B = 30.36, P = 0.01) in the obese group.
Conclusion: Our findings suggest ferritin is associated with IR in obese women and with anti-oxidative status in non-obese 
women. Further studies are warranted to elucidate the precise role of ferritin in obesity.
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INTRODUCTION
Serum ferritin concentration is an indicator of the total 
amount of stored iron in the body,1) which is necessary to 
maintain the appropriate supply of oxygen and enzymes to 
cells and tissues.2) Ferritin is also related to oxidative stress and 
excessive activation of reactive oxygen species, which contributes 
to the development of insulin resistance (IR), atherosclerosis and 
cardiovascular disease.3,4) Several clinical studies have shown that 
elevated ferritin levels are associated with IR, diabetes mellitus 
Jee-Yon Lee, et al: Association of Ferritin with Anti-oxidative Status and Insulin Resistance
206  |  Vol. 33, No. 4 Jul 2012 Korean J Fam Med
and metabolic syndrome.5-7)
However, Schulpis et al.8) showed conflicting data with regard 
to the relationship between ferritin and anti-oxidant status. The 
total anti-oxidant status increased as ferritin levels increased in a 
group of phenylketonuria patients on a high antioxidant diet. In 
addition, the protective role of ferritin against oxidative stress was 
confirmed by several in vivo studies. Cells enriched by ferritin 
showed an enhanced resistance to oxidative stress, whereas cells 
in which ferritin was downregulated had reduced resistance to 
oxidative stress.9) Although the role of ferritin as an anti-oxidant 
has remained largely hypothetical, ferritin is known to play an 
anti-oxidative role by sequestering iron, which damages cells 
through oxidative reactions.10)
The reason for this discrepancy is unclear at present, but 
could possibly be attributed to differences in metabolic conditions 
and ethnicity. Currently, few studies have considered the role 
of obesity in the relationship between ferritin and metabolic 
parameters. Therefore, the aim of this study was to evaluate the 
association between serum ferritin levels and cardio-metabolic 
risk factors and the anti-oxidative status in healthy obese and non-
obese women.
METHODS
1. Study Population
Study subjects were recruited through an advertisement at a 
health promotion center of a women’s hospital in Seoul, South 
Korea from 2009 to 2010. A total of 87 non-obese and 24 obese 
women between the ages of 32 and 68 years were included in 
the study. Participants were current non-smokers, had a low 
alcohol consumption (<2 drinks per week) and were not using 
medications or supplements that could affect cardio-metabolic 
function. The study complied with the Declaration of Helsinki, 
and the review board of Yonsei University College of Medicine 
approved this study. The institutional review board approval 
number is 4-2011-0483.
All participants were healthy and had no previous diagnosis 
or evidence of cardiovascular disease, diabetes, moderate to 
severe hypertension (resting blood pressure [BP] >170/100 mm 
Hg), kidney disease, or liver disease on physical examination. 
We also excluded any patients with anemia (ferritin <10 μg/L, 
hemoglobin <12 g/dL).
2. Methods
Height, to the nearest 0.1 cm, and weight, to the nearest 0.1 
kg, were measured with an automatic height-weight scale, and 
body mass index (BMI, kg/m2) was calculated as weight divided 
by height squared. Obesity was defined as a BMI greater than 
25 kg/m2, according to the Western Pacific Region of the World 
Health Organization criteria for obesity.11)
Biochemical testing was performed on blood samples 
collected after study participants had fasted for at least eight hours. 
Serum levels of fasting glucose, ferritin, total cholesterol, high 
density lipoprotein cholesterol (HDL-C), and triglycerides (TG) 
were assayed using an ADIVA 1650 chemistry system (Bayer, 
Tarrytown, NY, USA). Low density lipoprotein cholesterol 
was calculated using Friedwald’s formula. Fasting insulin was 
assayed by electrochemiluminescence immunoassay using an 
Elecsys 2010 (Roche, Indianapolis, IN, USA). High sensitivity 
C-reactive protein (hsCRP) was measured by a latex-enhanced 
immunoturbidimetric assay using an ADIVA 1650 chemistry 
system. IR was estimated by the homeostasis model assessment 
of insulin resistance (HOMA-IR) index: (insulin [μIU/mL] × 
fasting blood glucose [mg/dL] / 18) / 22.5.
Plasma total anti-oxidant status (TAS) was measured via the 
colorimetric method using a Radox total anti-oxidant status kit 
(Radox Laboratories Ltd., San Francisco, CA, USA). The intra- 
and inter-assay coefficients of variation were 3.08% and 3.75%, 
respectively.
3. Statistical Analysis
Data are expressed as the mean ± SD for normally distributed 
data and as the median and interquartile range for non-normally 
distributed data. After systolic BP, diastolic BP, HDL-C, TG, 
hsCRP, ferritin, insulin, HOMA-IR, and uric acid levels were 
logarithmically transformed to eliminate the skewness of the 
distribution, Pearson’s correlation coefficients were calculated 
to evaluate the relationship between serum ferritin and other 
metabolic parameters. Additionally, a stepwise multiple linear 
regression analysis was performed to identify factors contributing 
to serum ferritin levels in the non-obese and obese groups. 
Statistical significance was defined as a P-value < 0.05. All 
calculations were performed using the SPSS ver. 18.0 (SPSS Inc., 
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Chicago, IL, USA).
RESULTS
1. Clinical Characteristics
The clinical characteristics of the two study groups are shown 
in Table 1. The obese group had a significantly higher age, systolic 
BP, diastolic BP, BMI, TG, and fasting blood glucose levels (all P < 
0.05). The median ferritin concentration was 57.10 (range, 34.17 
to 94.04) μg/L in the non-obese group and 73.05 (range, 41.23 
to 130.60) μg/L in the obese group.
2. Correlation between Ferritin Levels and 
Clinical Variables
Ferritin levels were positively correlated with age (r = 0.38, 
P < 0.001), BMI (r = 0.24, P = 0.01), HOMA-IR (r = 0.20, P = 
0.04) and TAS (r = 0.38, P < 0.001), as shown in Table 2. In the 
subgroup analysis, ferritin levels were positively correlated with 
age (r = 0.39, P < 0.001) and TAS (r = 0.43, P < 0.001) in the 
non-obese group, and positively correlated with fasting insulin (r 
= 0.50, P = 0.02) and HOMA-IR (r = 0.52, P = 0.01) in the obese 
group, as shown in Table 2.
3. Multiple Linear Regression Assessment for 
Independent Relationships between Ferritin 
and Clinical Variables
In the stepwise multiple regression analysis, TAS level was 
identified as the explanatory variable accounting for serum ferritin 
levels in the non-obese group, and HOMA-IR was determined to 
be the explanatory variable accounting for serum ferritin levels in 
the obese group (Table 3).
DISCUSSION
Ferritin is known to have biphasic roles in the body’s response 
to oxidative stress; nevertheless, the role of ferritin in humans has 
Table 1. Clinical and metabolic variables of the non-obese versus obese study group.
Variables Non-obese (n = 87) Obese (n = 24) P-value
Age (y) 53.26 ± 11.12 60.75 ± 3.73 <0.001
Body mass index (kg/m2) 22.23 ± 1.70 26.97 ± 1.41 <0.001
Systolic blood pressure (mm Hg) 122.00 (110.00-135.00) 131.00 (120.75-137.75) 0.02
Diastolic blood pressure (mm Hg) 73.00 (63.00-80.00) 77.00 (72.25-83.75) 0.03
Total cholesterol (mg/dL) 185.15 ± 33.42 194.25 ± 30.82 0.23
High density lipoprotein cholesterol (mg/dL) 53.00 (49.00-60.00) 55.50 (51.00-61.75) 0.66
Low density lipoprotein cholesterol (mg/dL) 108.97 ± 29.66 106.73 ± 28.93 0.74
Triglyceride (mg/dL) 95.00 (66.00-120.00) 125.50 (98.75-200.00) 0.01
Fasting glucose (mg/dL) 86.75 ± 10.33 92.92 ± 8.88 0.01
Insulin (mU/L) 4.03 (2.58-6.08) 5.33 (3.30-6.70) 0.22
HOMA-IR 0.81 (0.59-1.35) 1.26 (0.78-1.61) 0.11
High sensitive C-reactive protein (mg/L) 0.01 (0.00-0.04) 0.04 (0.01-0.17) 0.32
Uric acid (mg/dL) 4.00 (3.40-4.75) 4.05 (3.28-5.48) 0.76
Total anti-oxidant status (nmol/L) 1.28 ± 0.10 1.32 ± 0.07 0.13
Ferritin (µg/L) 57.10 (34.17-94.04) 73.05 (41.23-130.60) 0.11
Values are presented as mean ± SD. Skewed data are presented as medians (range).
P-values are calculated by the t-test (normal distribution), Wilcoxon’s rank sum test (non-normal distribution).
HOMA-IR: homeostasis model assessment of insulin resistance.
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not been fully clarified. As a pro-oxidant, iron plays a key role in 
converting poorly reactive free radicals into highly reactive free 
radicals.12) It has been hypothesized that iron contributes to IR by 
damaging pancreatic beta cells with reactive hydroxyl radicals.13,14)
In contrast, the protective role of ferritin against oxidative 
stress has been confirmed by several experiments. Balla et al.15) 
reported that cells pretreated with ultraviolet A radiation, which 
up-regulates the synthesis of ferritin, had elevated anti-oxidant 
activity. Similar results were obtained with human leukemia cells 
inundated with various types of oxidative stress.9) The possible 
Table 2. Correlations between ferritin levels and cardio-metabolic risk factors and anti-oxidative status.
Total (n = 111) Non-obese (n = 87) Obese (n = 24)
r P-value r P-value r P-value
Age (y) 0.38 <0.001 0.39 <0.001 0.28 0.19
Body mass index (kg/m2) 0.24 0.01 0.09 0.43 0.39 0.06
Systolic BP (mm Hg) 0.11 0.25 0.13 0.25 -0.12 0.59
Diastolic BP (mm Hg) 0.10 0.29 0.13 0.24 -0.14 0.50
Total cholesterol (mg/dL) 0.12 0.20 0.17 0.11 -0.10 0.65
Triglyceride (mg/dL) 0.11 0.25 0.16 0.14 -0.11 0.60
LDL-C (mg/dL) 0.07 0.44 0.11 0.30 0.00 0.98
HDL-C (mg/dL) 0.05 0.64 0.08 0.46 -0.11 0.61
Fasting glucose (mg/dL) 0.17 0.07 0.11 0.32 0.23 0.27
Insulin (mU/L) 0.17 0.08 -0.01 0.92 0.50 0.02
HOMA-IR 0.20 0.04 0.00 0.99 0.52 0.01
TAS (nmol/L) 0.38 <0.001 0.43 <0.001 0.19 0.38
hsCRP (mg/L) 0.09 0.35 0.03 0.79 0.10 0.64
Uric acid (mg/dL) 0.05 0.60 0.10 0.38 -0.06 0.80
Coefficient (r) and P-values were calculated by Pearson’s correlation analysis. Systolic BP, diastolic BP, HDL-C, triglyceride, hsCRP, ferritin, 
insulin, HOMA-IR, and uric acid levels were logarithmically transformed before statistical analysis to approximate a normal distribution.
BP: blood pressure, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, HOMA-IR: homeostasis 
model assessment of insulin resistance, TAS: total anti-oxidant status, hsCRP: high sensitive C-reactive protein.
Table 3. Multiple regression analysis to identify independent relationships between ferritin and clinical variables.
Variables β coefficient SE Model r2 P-value
Non-obese*
    TAS 177.16 50.73 0.18 <0.0001
Obese†
    HOMA-IR 30.36 10.98 0.27 0.01
All variables left in the model were significant at the 0.15 level. No other variables met the 0.15 significance criterion for entry into the 
model. Variables included in the stepwise model: age, body mass index, systolic blood pressure, ferritin, HOMA-IR, hsCRP, glucose, 
cholesterol, HDL-C, TG, and TAS. Systolic blood pressure, ferritin, HOMA-IR, hsCRP, HDL-C, and TG were logarithmically transformed 
before statistical analysis to approximate normal distribution.
TAS: total anti-oxidant status, HOMA-IR: homeostasis model assessment of insulin resistance, hsCRP: high sensitive C-reactive protein, 
HDL-C: high density lipoprotein cholesterol, TG: triglyceride.
*Data from a total of 87 non-obese women. †Data from a total of 24 obese women.
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mechanism underlying the anti-oxidative effects of ferritin is 
its capacity to bind to nitric oxide molecules,16) which have 
anti-oxidative properties, and to decrease lipid peroxidation by 
sequestering iron in solution.17)
Despite the fact that ferritin’s ability to act against oxidative 
stress is regulated by many proteins that sequester and mobilize 
iron,18) the precise factors and pathophysiology that regulate 
the homeostasis between the anti-oxidant and pro-oxidant 
properties of ferritin are not clear. In the present study, we found 
that serum ferritin levels were significantly correlated with IR (as 
measured by HOMA-IR) in obese women, even after adjusting 
for potential covariates that are known to be linked to IR. This 
result is consistent with that of previous studies.19) However, these 
relationships were not found in the non-obese group. On the 
contrary, TAS was positively correlated with serum ferritin levels 
in the non-obese group. TAS is a valuable method for detecting 
the actual total anti-oxidant status in humans.20) In previous 
studies, TAS levels showed negative relationships with coronary 
atherosclerosis, dyslipidemia, and essential HTN.21-23) Our 
findings suggest that ferritin is associated with the anti-oxidative 
status of non-obese women. Several possible mechanisms of 
ferritin against oxidative stress have been proposed, however, the 
protective roles of ferritin against IR and metabolic syndrome 
have not been evaluated in previous studies. Our findings suggest 
that in non-obese women, increased ferritin levels might have 
protective roles against diseases related to oxidative stress, and 
further studies are warranted to evaluate these relationships.
The reason for the differing metabolic role of ferritin in obese 
and non-obese women remains uncertain. However, one possible 
mechanism for this association is related to adipocytokines 
derived from fat tissue, which are known to affect oxidative stress 
and IR.24) Increased fat mass can change adipose biology and alter 
adipocyte-secreted protein expression.25) Thus, the difference in 
adiposity between obese and non-obese women may affect the 
role of adipocytokines associated with oxidative status and IR.
Ikegami et al.26) demonstrated that adiponectin upregulates 
ferritin heavy chain in murine skeletal muscle tissues. Adiponectin 
is an adipocyte-derived protein known to reduce IR.27,28) 
Conversely, in a study of obese adolescents, tumor necrosis 
factor-a and IL 6 levels, both of which are pro-inflammatory 
cytokines released by adipocytes, were elevated as ferritin levels 
increased.29)
Therefore, adipocytokines may play a role in regulating the 
equilibrium between the pro-oxidant and anti-oxidant properties 
of ferritin in non-obese and obese women. Further studies are 
needed to explore the pathogenesis of the biphasic role of ferritin 
in obesity.
The present study has several limitations. The cross-
sectional design limits our ability to determine causality. The 
small sample size is another limitation of this study. Additional 
longitudinal studies with larger samples are necessary to confirm 
our findings. Although our study had some limitations, this is, to 
our knowledge, the first study to assess the association between 
ferritin and anti-oxidative status and IR in order to evaluate the 
effect of BMI on this association. In conclusion, the serum ferritin 
level was independently associated with anti-oxidant status in 
non-obese women and with IR in the group of obese women. 
Further studies are warranted to elucidate the precise role of 
serum ferritin in obesity.
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